Investors in UroGen Pharma (NASDAQ:URGN) Have Unfortunately Lost 42% Over the Last Five Years

Yahoo FinanceOct 19 22:32

TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating

Futu NewsOct 16 20:31 · Ratings

Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $40

Futu NewsOct 16 20:31 · Ratings

UroGen Announces FDA Acceptance Of Its New Drug Application For UGN-102 For Intravesical Solution

BenzingaOct 16 04:32

UroGen Announces FDA Acceptance of Its New Drug Application for UGN-102

UroGen PharmaOct 15 12:00

UroGen Started at Buy by EF Hutton, RTGel Technology Cited

Seeking AlphaOct 15 00:25